Camp4 Therapeutics

Company snapshot

At CAMP4 Therapeutics, we are pioneering a novel approach to programmable therapeutics. We combine a deep understanding of regulatory RNA and gene expression with a complementary and customizable oligonucleotide modality. Our platform’s proprietary insights enable us to harness the power of RNA to upregulate the expression of genes and unlock the potential to create treatments for hundreds of dise

• 9 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 US patent(s) indexed to this assignee profile.
• 9 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Camp4 Therapeutics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Camp4 Therapeutics.

1. Jun 8, 2026 Clinical update

   CPS-101 — Phase 1

2. Jun 8, 2026 Clinical update

   Ketamine Hydrochloride — Phase 3

3. Jun 8, 2026 Clinical update

   Conventional sound generator (SG) — Phase 3

4. Jun 8, 2026 Clinical update

   Active smoked cannabis — Phase 2

5. Jun 5, 2026 Clinical update

   Virtual Reality Exposure Therapy - Dynamic — Phase 3

View all clinical trial activity →

• What is Camp4 Therapeutics?

  Camp4 Therapeutics is a pharma organization headquartered in Cambridge, USA. It trades on NYSE under ticker CAMP. Primary therapeutic focus areas include Urea cycle disorders (UCD), Cannabis Smoking, Subjective Tinnitus, Chronic Migraine, Suicide. NovaPharmaNews links 9 clinical

• Is Camp4 Therapeutics publicly traded?

  Yes. Camp4 Therapeutics is listed with ticker CAMP on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Camp4 Therapeutics develop or market?

  We link 15 drug profile(s) where Camp4 Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/camp4-therapeutics-corp#company-drugs.

• What are the latest developments for Camp4 Therapeutics?

  In the last 12 months our linked public records show 9 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Camp4 Therapeutics focus on?

  Camp4 Therapeutics focuses on Urea cycle disorders (UCD), Cannabis Smoking, Subjective Tinnitus based on our analysis of their pipeline programs and drug development activities.